Skip to playerSkip to main content
Benzinga
  • 3 years ago
Pfizer's RSV vaccine Abrysvo saw $375 million in sales in its first 5 months on the market and is seeing "very fast uptake," according to Pfizer's Chief Commercial Officer. Abrysvo is approved to prevent RSV in older adults and through maternal vaccination to protect infants. Declining sales of COVID treatments and vaccines like Paxlovid and Comirnaty caused Pfizer's overall third-quarter revenues to drop 41% to $13.2 billion, excluding COVID product sales were up 10%. Pfizer is exploring expanding into obesity treatment with its oral GLP-1 candidate danuglipron, with Phase 2b results expected before year-end. It aims to quickly move the candidate into Phase 3 trials.
Transcript
00:00 Benzinga and here's what's on the block. Pfizer's RSV vaccine Abrisvio saw $375 million in sales in
00:06 its first five weeks on the market and is seeing very fast uptake, according to Pfizer's chief
00:11 commercial officer. Abrisvo is approved to prevent RSV in older adults and through maternal
00:15 vaccination to protect infants. Declining sales of COVID treatments and vaccines like PaxLavid
00:20 and Comirnaty caused Pfizer's overall third-quarter revenues to drop 41% to $13.2 billion,
00:26 excluding COVID product sales were up 10%. Pfizer is exploring expanding its obesity treatment with
00:31 its oral GLP-1 candidate, Craniofibroma, with phase 2b results expected before year end.
00:36 For all things money visit Benzinga.com
Comments